Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04714372 · ClinicalTrials.gov registry record · Phase 1
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04714372 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 9 participants.
The verdict
NCT04714372, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Daratumumab/rHuPH20
- DRUG FT538
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04714372
The ClinicalTrials.gov registry entry for NCT04714372 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04714372 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04714372 about?
NCT04714372 is a clinical study titled "FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia". This Phase I open-label dose escalation study is conducted in two stages with a primary endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and related myeloid diseases.
What is the current status of trial NCT04714372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2021-11-03. Estimated completion is 2024-10-15.
What interventions are being tested in trial NCT04714372?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab/rHuPH20 (DRUG), FT538 (DRUG).
Who is sponsoring clinical trial NCT04714372?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.